MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Nobles Medical Technology 2, a provider of cardiovascular closure solutions, announced it received FDA approval to resume its NobleStitch EL clinical trial for patent foramen ovale (PFO) closure. The minimally invasive device uses a suture-only method to close the small opening between the heart’s upper chambers, offering a potential alternative to metal implants. The company paused enrollment earlier this year following requests for additional safety and performance data, which it says have now been addressed.
A Pre-Market Approval will be submitted upon completion of the study, with patient enrollments set to continue in the last quarter of 2025. The device utilizes a proprietary percutaneous suturing technique to close defects without requiring a permanent implant.
Posted by MedCloudInsider Editors on 10/07/20250 comments
ZEISS, one of the leading medical technology companies listed on the MDAX and TecDAX of the German stock exchange, expanded its ophthalmic portfolio with new surgical instruments and digital workflow capabilities aimed at improving efficiency and visualization in vitreoretinal surgery. The updates enhance integration between DORC devices and ZEISS’s digital surgery platforms, allowing real-time data capture and imaging within a connected ecosystem. The company said the expansion supports improved surgical precision and workflow standardization across operating rooms.
The announcement underscores ZEISS’s effort to lead in connected surgical ecosystems, the company said. This is an area seeing rapid digitalization. ZEISS’s combined focus on instrumentation and digital connectivity aims to differentiate it in the next phase of ophthalmic device innovations.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Xenocor, a Utah-based medical device company dedicated to transforming surgical visualization, announced it has received a U.S. patent for its next-generation single-use medical borescope technology, designed to improve visualization during minimally invasive procedures. The patented system integrates a lightweight optical sensor and advanced image-processing algorithms, enabling high-resolution imaging without the need for reusable or sterilized components. The company stated that the design reduces the risk of infection and lowers maintenance costs for hospitals and surgical centers.
The patent aligns with healthcare’s shift toward disposable, infection-resistant medical devices, the company said. Xenocor’s approach, which combines affordability with real-time image quality, could appeal to smaller facilities seeking to modernize their surgical imaging without incurring significant capital investments.
Posted by MedCloudInsider Editors on 10/07/20250 comments
WaveBreak Therapeutics, a biopharmaceutical company developing a new class of therapeutics for the treatment of neurodegenerative diseases, has published new data demonstrating that its experimental compound, WTX-607, binds to and reduces alpha-synuclein aggregates in human brain tissue. The findings, shared at the International Congress of Parkinson's Disease and Movement Disorders, suggest that WTX-607 could slow or prevent neurodegeneration associated with Parkinson’s disease and Lewy body dementia. The company stated that the molecule penetrates brain tissue efficiently and has demonstrated efficacy in multiple preclinical models.
The announcement adds to a growing body of research targeting alpha-synuclein, a hallmark protein in Parkinson’s pathology. The success of the preclinical trials positions WTX-607 as a potential treatment for Parkinson's disease and Lewy body dementia.
Posted by MedCloudInsider Editors on 10/07/20250 comments
OutcomeMD has introduced the Patient Experience Data Network, the first data intelligence network powered by patient-reported outcomes (PROs). The platform aggregates de-identified data from healthcare organizations using OutcomeMD’s digital tools to measure how patients feel and function after treatment. Participating sites can benchmark outcomes, compare therapies, and access dashboards that link clinical claims and PRO data for research or value-based care initiatives. The launch aims to collect high-quality data to extract actionable insights that enable innovation and improvements in healthcare.
The Patient Experience Data Network shows patients that they are being heard and that their lived experiences are being recorded for future use, the company said.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Benchling, provider of a cloud-based platform for biotechnology research and development, has launched Benchling AI, a suite of generative and predictive tools built to streamline scientific workflows across drug discovery, biomanufacturing, and genomics. The platform integrates directly with Benchling’s cloud-based data system, enabling researchers to query experiments in natural language, generate molecular annotations, and surface insights from structured and unstructured datasets. Benchling CEO Sajith Wickramasekara stated, "The goal is to put AI in the hands of every scientist and bend the speed and cost curve of making medicines." Benchling AI features agents, including the Deep Research Agent, Data Entry Agent, and Compose Agent, enabling scientists to access models in one place for optimized experiments.
The launch comes amid growing investment in AI for scientific research. Benchling claims its advantage lies in its integration with existing lab workflows, providing scientists with AI assistance within the data platforms they already use. A top 20 biopharma company has already utilized Benchling’s Deep Research Agent, reducing project length by eight months.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Medtronic announced FDA approval of the Altaviva device, designed to treat urge urinary incontinence (UUI). The device is a minimally invasive, implantable tibial neuromodulation (ITNM) therapy inserted near the ankle. Altaviva is intended for patients who do not feel comfortable with invasive therapies, given the potential side effects.
The device is designed to have a 15-year battery lifespan, requiring no daily adjustments. It is MRI compatible and requires only 30 minutes of recharging. Medtronic, which has been investing heavily in connected care, is positioning Altaviva as part of its broader strategy to expand patient access and simplify treatment.
Posted by MedCloudInsider Editors on 09/26/20250 comments
The US Marine Corps has renewed its contract with defense tech company Tagup to continue using its AI-powered logistics platform, Manifest, for battlefield medical support. Manifest replaces legacy systems that often led to expired supplies, overstocked warehouses, or delayed missions. The AI tool is designed to optimize inventory management and accelerate the delivery of critical medical equipment to deployed forces.
The renewal comes as the US Marine Corps aims to adopt a modernized approach to logistics, utilizing AI to ensure speed and precision. By keeping Tagup in its toolkit, the Marine Corps signals confidence in smaller defense tech firms to deliver agile solutions alongside larger contractors. It also ensures that Marines can receive the necessary medical supplies, regardless of the condition.
Posted by MedCloudInsider Editors on 09/26/20250 comments
The Consumer Technology Association (CTA) has announced a new Health AI standard, CTA2135: Performance Verification and Validation for Predictive Health AI Solutions. This standard is designed to ensure predictive AI tools in healthcare are accurate, reliable, and ready for deployment. The announcement was made at the CTA’s Health AI+ event at Hopkins Bloomberg Center.
CTA President Kinsey Fabrizio emphasized how the new standard is aimed at helping developers to fulfill AI’s promise of solving significant challenges that address patient and provider needs.
Also released was a CTA research report titled "AI’s Impact and Opportunity Among Healthcare Practitioners," which finds that although AI adoption in healthcare is still nascent, many clinicians are optimistic about what the tools could do, especially for reducing administrative burden, improving documentation, and freeing up time for patient care. The new CTA-2135 release is another of CTA’s extensive portfolio of health-focused AI standards and research.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Olympus has launched the VISERAS OTV-S500, its newest imaging platform, designed for ear, nose, and throat (ENT) and urological procedures. The system is designed for both office and outpatient settings, offering flexible and rigid endoscope compatibility, along with a built-in lighting system that supports switching between white light, stroboscopy mode, and Narrow Band Imaging (NBI).
A key feature of the VISERA S system is its tight integration with Olympus’s content management tools, including the nCare medical recorder and VaultStream system, enabling clinicians to capture procedural recordings and share data across sites within a facility. Olympus also emphasized that NBI technology has been shown to reduce recurrence in non-muscle invasive bladder cancer (NMIBC) by about 37% over a follow-up period of 1,235 months compared with white light cystoscopy alone. The VISERA S Video is not suitable for cardiac applications, but its main features include improved color, depth, and resolution for a clear view of vascular structures.
Olympus Corporation is a global medical technology company committed to providing minimally invasive treatments to improve patient outcomes with elevated standards of care.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Eleos Health has launched Groups, a feature in its documentation platform aimed at simplifying individual speaker notes from group substance use disorder (SUD) therapy sessions. The new tool automatically produces individual speaker summaries from group sessions, whether in-person or via telehealth, while ensuring privacy standards are met to help organizations maintain compliance and reduce administrative overhead.
The Groups capability works with any EHR system and integrates with Eleos’s existing documentation tools. Audio is processed in real time in a HIPAA-compliant environment; Eleos does not save raw session audio, protecting patient privacy. According to Eleos, the solution helps clinicians generate more than 80% of progress note content, with over 90% of notes submitted within 24 hours, and reduces documentation time by over 70%.
Eleos serves more than 200 organizations and more than 35,000 providers. CEO Alon Joffe said the tool supports scaling group therapy sustainably and improving revenue consistency for SUD treatment entities. The key benefits of Groups will help SUD organizations with a reduction in admin, streamlined documentation and provides support to clinical teams by freeing up time. Eleos will demonstrate the new feature at its Summer Launch Event on September 17.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Intrinsic Therapeutics, a medical technology company, has successfully implanted its Barricaid Annular Closure Device in several patients while they remained awake, marking the first time this procedure has been done without general anesthesia. Dr. Ernest E. Braxton Jr., a neurosurgeon specializing in awake and minimally invasive spine surgery, performed the operations in Vail, Colorado.
The new approach uses local and regional anesthesia, enabling patients to provide real-time feedback during the procedure to confirm that nerve pressure has been relieved. Dr. Braxton has been performing awake surgery for more than a decade. Some benefits include a faster recovery period, reduced pain, and fewer risks commonly associated with general anesthesia, such as nausea or postoperative confusion.
Barricaid is a device designed to reduce reherniation and reoperation rates in patients with significant annular defects following lumbar discectomy surgery. It has been implanted in more than 12,000 patients, with clinical studies, including randomized controlled trials and six single-arm studies.
Posted by MedCloudInsider Editors on 09/21/20250 comments